Rubric Capital Management (New York)’s Antares Pharma, Inc. ATRS Stock Holding History

Rubric Capital Management (New York)’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,900,000	Closed	-$44.7M	–	99
2022 Q1	$44.7M	Buy	10,900,000 +100,000	+0.9%	+$363K	1.62%	18
2021 Q4	$38.6M	Buy	10,800,000 +800,000	+8%	+$2.8M	1.82%	22
2021 Q3	$36.4M	Buy	10,000,000 +500,000	+5%	+$2.02M	1.02%	25
2021 Q2	$41.4M	Buy	9,500,000 +777,353	+9%	+$3.17M	2.61%	17
2021 Q1	$35.9M	Buy	8,722,647 +5,152,084	+144%	+$22.3M	2.09%	21
2020 Q4	$14.2M	Buy	+3,570,563	New	+$11.6M	1.05%	37
2019 Q1	–	Sell	-12,865	Closed	-$35K	–	73
2018 Q4	$35K	Buy	+12,865	New	+$42.4K	﹤0.01%	49
2017 Q4	–	Sell	-324,076	Closed	-$1.05M	–	64
2017 Q3	$1.05M	Sell	324,076 -2,864,524	-90%	-$8.84M	0.1%	54
2017 Q2	$10.3M	Buy	3,188,600 +816,630	+34%	+$2.31M	2.12%	21
2017 Q1	$6.74M	Buy	2,371,970 +1,207,622	+104%	+$2.9M	1.96%	24
2016 Q4	$2.71M	Buy	+1,164,348	New	+$2.22M	0.93%	26

Other funds holding ATRS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rubric Capital Management (New York)'s ATRS Position: Q2 2022 in Review

Rubric Capital Management (New York) sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 10,900,000 shares — an estimated $44.7M sold.

Rubric Capital Management (New York) first reported a position in ATRS in Q4 2016 and held it in 11 quarters. The position peaked at $44.7M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

Rubric Capital Management (New York) reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
Rubric Capital Management (New York) sold 10,900,000 Antares Pharma, Inc. shares in Q2 2022, an estimated $44.7M.
Rubric Capital Management (New York) first reported a position in Antares Pharma, Inc. in Q4 2016 and held it in 11 quarters.
Rubric Capital Management (New York)'s Antares Pharma, Inc. position peaked at $44.7M in Q1 2022.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2022, filed 12 Aug 2022.